Efficacy and Safety of Ozanimod Hydrochloride for the Treatment of Moderately to Severely Active Ulcerative Colitis

white pills and prescription bottles
Investigators assessed the safety and efficacy of ozanimod as maintenance therapy for patients with moderately to severely active ulcerative colitis over a 52-week period.

For patients with ulcerative colitis (UC), ozanimod was found to be a more effective maintenance therapy than placebo. These findings, from a phase 3, multicenter, randomized, double-blind, placebo-controlled trial, were published in The New England Journal of Medicine.

Patients with moderately to severely active UC were recruited at 285 sites in 30 countries between 2015 and 2020; the study was funded by Bristol Myers Squibb. Patients in cohort 1 were randomly assigned in a 2:1 ratio to receive a 10-week induction regimen of 1 mg/day ozanimod hydrochloride (n=429) or placebo (n=216). Those in cohort 2 (n=367) received 10-weeks open-label ozanimod. All treatment responders (n=457) were randomly assigned in a 1:1 ratio to receive maintenance therapy with ozanimod (n=230) or placebo (n=227) through week 52. Efficacy and safety were assessed.

Recipients of the cohort 1 ozanimod, cohort 2 ozanimod, and placebo treatments were aged mean 41.4, 42.1, and 41.9 years; 57.1%, 58.3%, and 66.2% were men; total Mayo scores were 8.9, 9.1, and 8.9; and UC diagnosis occurred 6.9, 7.9, and 6.8 years prior, respectively.

At week 10, 18.4% of ozanimod and 6.0% of placebo recipients were in clinical remission (P <.001). Similar group differences were reported for clinical response (47.8% vs 25.9%; P <.001), endoscopic improvement (27.3% vs 11.6%; P <.001), and mucosal healing (12.6% vs 3.7%; P <.001), respectively.

At week 52, 37.0% of ozanimod and 18.5% of placebo recipients were in clinical remission (P <.001). Similar group differences were observed for clinical response (60.0% vs 41.0%; P <.001), endoscopic improvement (45.7% vs 26.4%; P <.001), glucocorticoid-free remission (31.7% vs 16.7%; P <.001), mucosal healing (29.6% vs 14.1%; P <.001), maintenance of remission (52% vs 29%; P =.002), and durable remission (17.8% vs 9.7%; P =.003), respectively.

During the maintenance period, 49.1% of the ozanimod and 36.6% of the placebo cohorts had an adverse event and 5.2% and 7.9%, a serious adverse event, respectively. A total of 3 participants discontinued ozanimod and 6 discontinued placebo due to adverse events. Ozanimod was associated with increased infection rates (23.0% vs 11.9%, respectively).

This study was limited by its relatively short maintenance period; however, an open-label extension study is ongoing.

The study authors concluded that ozanimod was more effective at treating moderate to severe UC than placebo.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

Reference

Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291. doi:10.1056/NEJMoa2033617